Edition:
United States

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Capital Market

1.99USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$1.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,956
52-wk High
$55.00
52-wk Low
$1.64

Chart for

About

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based... (more)

Overall

Beta: 2.23
Market Cap(Mil.): $3.86
Shares Outstanding(Mil.): 1.95
Dividend: --
Yield (%): --

Financials

  NVIV.OQ Industry Sector
P/E (TTM): -- 44.43 31.56
EPS (TTM): -98.78 -- --
ROI: -147.75 7.97 12.88
ROE: -155.69 11.63 15.04

BRIEF-Invivo Therapeutics Reports Q1 Loss Per Share Of $3.34

* INVIVO THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

May 07 2018

BRIEF-Invivo Therapeutics Files For Offering Of Up To $8 Mln Shares

* INVIVO THERAPEUTICS HOLDINGS CORP FILES FOR OFFERING OF UP TO $8 MILLION SHARES OF COMMON STOCK, WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING Source text (https://bit.ly/2HrYEIM) Further company coverage:

Apr 24 2018

BRIEF-Invivo Therapeutics Announces Reverse Stock Split

* ANTICIPATES REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 5:00 P.M. EASTERN TIME ON APRIL 16, 2018

Apr 09 2018

BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™

* INVIVO THERAPEUTICS RECEIVES FDA APPROVAL FOR PIVOTAL, RANDOMIZED, CONTROLLED TRIAL OF THE NEURO-SPINAL SCAFFOLD™ IN PATIENTS WITH ACUTE SPINAL CORD INJURY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 08 2018

Earnings vs. Estimates